Reframing Therapeutic Development in Uterine Leiomyosarcoma: A Genomic Instability–Directed Strategy

Abstract excerpt

Uterine leiomyosarcoma (uLMS) is an aggressive uterine cancer with limited durable benefit from current systemic therapy. Genomic profiling shows recurrent inactivation of TP53, RB1, and ATRX, leading to genomic instability, complex copy-number alterations, and telomere dysfunction via alternative lengthening of telomeres. Additional events in the PTEN and PI3K–AKT–mTOR pathways occur, and a minority of tumors har...

Topics

Open a Topic to create a Post that cites this publication.

• Leiomyosarcoma
• Metabolic Networks and Pathways
• Molecular Targeted Therapy
• Ovarian cancer diagnosis and treatment
• Phthalazines
• Sarcoma Diagnosis and Treatment
• Uterine Myomas and Treatments
• Uterine Neoplasms

Identifiers and source

Literature Corpus work

cc107a3a-1339-52fb-aeea-ba19f8f934c3

DOI

10.20944/preprints202606.1394.v1